
## Maria Agostina Cinellu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2535350/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Caged noble metals: Encapsulation of a cytotoxic platinum(II)-gold(I) compound within the ferritin nanocage. International Journal of Biological Macromolecules, 2018, 115, 1116-1121.	7.5	23
2	Gold compounds as cysteine protease inhibitors: perspectives for pharmaceutical application as antiparasitic agents. BioMetals, 2017, 30, 313-320.	4.1	24
3	Ferritin nanocages loaded with gold ions induce oxidative stress and apoptosis in MCF-7 human breast cancer cells. Dalton Transactions, 2017, 46, 15354-15362.	3.3	37
4	Gold-based drug encapsulation within a ferritin nanocage: X-ray structure and biological evaluation as a potential anticancer agent of the Auoxo3-loaded protein. Chemical Communications, 2016, 52, 9518-9521.	4.1	43
5	Cytotoxic properties of a new organometallic platinum( <scp>ii</scp> ) complex and its gold( <scp>i</scp> ) heterobimetallic derivatives. Dalton Transactions, 2016, 45, 579-590.	3.3	47
6	Interactions of gold-based drugs with proteins: crystal structure of the adduct formed between ribonuclease A and a cytotoxic gold(iii) compound. Metallomics, 2014, 6, 233-236.	2.4	49
7	Inhibition of Na+/K+-ATPase and cytotoxicity of a few selected gold(III) complexes. Journal of Inorganic Biochemistry, 2014, 140, 228-235.	3.5	11
8	Protein Recognition of Gold-Based Drugs: 3D Structure of the Complex Formed When Lysozyme Reacts with Aubipy <sup>c</sup> . ACS Medicinal Chemistry Letters, 2014, 5, 1110-1113.	2.8	33
9	Interactions of gold-based drugs with proteins: the structure and stability of the adduct formed in the reaction between lysozyme and the cytotoxic gold(iii) compound Auoxo3. Dalton Transactions, 2014, 43, 17483-17488.	3.3	43
10	Thioredoxin reductase, an emerging target for anticancer metallodrugs. Enzyme inhibition by cytotoxic gold(iii) compounds studied with combined mass spectrometry and biochemical assays. MedChemComm, 2011, 2, 50-54.	3.4	94
11	Dinuclear Gold(III) Complexes as Potential Anticancer Agents: Structure, Reactivity and Biological Profile of a Series of Gold(III) Oxo-Bridged Derivatives~!2009-12-08~!2010-01-15~!2010-03-25~!. The Open Crystallography Journal, 2010, 3, 29-40.	0.4	12
12	Structural Characterization, Solution Studies, and DFT Calculations on a Series of Binuclear Gold(III) Oxo Complexes: Relationships to Biological Properties. Inorganic Chemistry, 2008, 47, 2368-2379.	4.0	102
13	Structural and Solution Chemistry, Antiproliferative Effects, and DNA and Protein Binding Properties of a Series of Dinuclear Gold(III) Compounds with Bipyridyl Ligands. Journal of Medicinal Chemistry, 2006, 49, 5524-5531.	6.4	189